Medical Veritas International, Inc.
Gary S. Goldman, Ph.D. is Pres./Founder of Medical Veritas International Inc., a non-profit 501(c)3 public charity that supports medical/scientific research and education. Since 2004, Dr. Goldman has served as Editor-in-Chief of Medical Veritas, a journal free from the conflicts of interest of the pharmaceutical industry. This journal was a 2009 Mom's Choice Awards® Silver Recipient in the area of Health, Nutrition, Fitness, & Safety.
Dr. Goldman serves as a reviewer for the Journal of the American Medical Association (JAMA), Vaccine, The American Journal of Managed Care (AJMC), Expert Review of Vaccines (ERV) and Expert Review of Dermatology (ERD) . He serves on the Editorial Board of Research and Reviews in Bioscience. His biography is included in Marquis’ 2005-2006 Who’s Who in Science and Engineering and 2006 Who’s Who in the World. Articles discussing Dr. Goldman's research have been published in JAMA, The Journal of American Physicians and Surgeons, Pediatrics, The International Journal of Toxicology, and Vaccine.
Whenever research concerning adverse vaccine effects is suppressed by health authorities, this is most disturbing, contrary to accepted scientific norms, and compromises professional ethics. Dr. Goldman, a health advocate, has written two books to raise awareness of health issues and call for accountability in medical research. Goldman's non-fiction book entitled, The Chickenpox Vaccine: A New Epidemic of Disease and Corruption received the Silver Award for adult non-fiction for 2008 Mom's Choice Awards and was an award-winning finalist in the Current Events: Political/Social category of the National Indie Excellence 2007 Book Awards.
Additional References:
Herpes zoster-related hospitalizations and expenditures before and after introduction of the varicella vaccine in the United States. Patel MS, Gebremariam A, Davis MM. Infect Control Hosp Epidemiol. 2009 May; 30(5):495-496.
RESULTS: Since the introduction of the chickenpox vaccine, hospitalization costs for complications of shingles have increased by more than $700 million annually for those over 60 years old.
A Population-Based Study of the Incidence and Complication Rates of Herpes Zoster Before Zoster Vaccine Introduction (Department of Research, Olmsted Medical Center, 210 Ninth St SE, Rochester, MN, USA. ) Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. Mayo Clin Proc 2007 Nov;82(11):1341-1349.
RESULTS: A total of 1669 adult residents with a confirmed diagnosis of HZ were identified between January 1, 1996, and December 31, 2001. Most (92%) of these patients were immunocompetent and 60% were women. When adjusted to the US adult population, the incidence of HZ was 3.6 per 1000 person-years (95% confidence interval, 3.4-3.7), with a temporal increase from 3.2 to 4.1 per 1000 person-years from 1996 to 2001.
Comparison of Shingles (HZ) Incidence Rates: Civen R et al. (2009) vs. Goldman GS (2005) Category
(age in years) | Cumulative
2000-2006
HZ incidence1
(95% C.I.) | Cumulative 2000-2003 HZ incidence2 |
Uncorrected
(95% C.I.) | Ascertainment-
Corrected |
| Vaccinated, 1-9 | 19 (15-25) | 14 (9-21) | 28 |
| Natural Disease, 1-9 | 239 (193-295) | 223 (180-273) | 446 |
| Natural Disease, 10-19 | 69 (61-77) | 61 (51-72) | 122 |
1The Incidence and Clinical Characteristics of Herpes Zoster Among Children and Adolescents After Implementation of Varicella Vaccination. Civen R, et al. The Pediatric Infectious Disease Journal, 2009 Nov; 28(11):1-6.
2Universal Varicella Vaccination: Efficacy Trends and Effect on Herpes Zoster. Goldman GS. International Journal of Toxicology, 2005 Jul/Aug; 24(4):203-213.